Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to email@example.com so that we can defer those challenges. Your health and safety are paramount to us.
Posted 01 September 2008
Regulatory leadership today is linked as never before to the management of global risk-specifically, global business risk.
This may be counterintuitive to those who have regarded regulatory affairs as the quasi-academic "documentation side" of drug development. But, in fact, the regulatory function in industry today is an increasingly critical platform for the management of business risk. The events and developments of the last 10 years (medical product failures, fallow pipelines, expiring patents, emergence of new and attractive but poorly understood markets) have created vast quantities of risks for the biopharmaceutical and medical device industries in the foreseeable future. Companies find themselves trying to emerge unscathed from this down-cycle, and in some cases possibly fighting for survival. And, many of these risks are related to regulated activities.
Regulatory Focus newsletters
All the biggest regulatory news and happenings.